11/18/2015 8:30 a.m. – Keynote Address: Kathy Hudson, Ph.D. NIH – 11th Annual Personalized Medicine Conference, November 18-19, 2015, Harvard Medical School
Reporter: Aviva Lev-Ari, PhD, RN
Live Press Coverage in REAL TIME
Director & Founder, Leaders in Pharmaceutical Business Intelligence, Boston
Co-Founder, GDE
8:30 a.m. – Keynote Address
The Impact of Precision Medicine on the Future of Healthcare
Kathy Hudson, Ph.D.
Deputy Director for Science, Outreach and Policy
National Insitutes of Health
- DIFFERENCES among individuals: GENES, LIFESTYLE, ENVIRONMENT
- MUST look beyond the Genome: diet, environment, behavior
FNIH Survey of Public Opinion on large US Cohort – 79% agree cohort probably need be done
54% participate in the Cohort
Participants as “Partners” not as “Subjects”
2015: President Obama launched $215 Million in the PMI for the NIH
- PMI Cohort $130
- PMI for Oncology $70
- FDA $10
- Health IT $5
PMI Working Group – 20 members
- Partners
- Harvard Pilgrims
- GE
- Intel
Assembling the PMI Cohort
- Recruitment denovo
- Lonngitudinal Cohort
- One Million Volumteers
- Direct volunteer – any one can sign up
- Healthcare provider Organizations
- Initial Core Data Set
- Policy for PMI Cohort Program
- IRB – Single Institutional Review Boards
- Privacy and Security
- Share results Clarify CLIA and HIPPA
- Information Flow In
- Participants will receive: Individual Data, individual Health Information, Ongoing study updates Aggregate results
- Required single institutional
- PMI Cohort Program Governance
- Program director
- executive committee
- steering v=committiee with 5 sub committiees
- data
- biobank
- resource access
IMPLEMENTATION
- underserved communities
- start with Volunteer ONLINE enrollement not with HC Provider Organizations
ANNOUNCMENT Four Funding Announcement for Cooperative Agreement
- Transaction Award Announcements
- National Search Outstanding Scientist to LEAD the PMI Cohort Program
- Appointment committee members
- Synch-4-Science Pilot
QUESTIONS from the AUDIENCE
- Q – Direct Volunteer Program – 1 Million Volunteer
- A – Pilot launched
- Q – Consumers of Health Care
- A –
9:00 a.m. – Panel Discussion
Investments in Personalized Medicine
During the past several years there have been increased levels of financial investments in fields related to Personalized Medicine. The new initiative on Precision Medicine by President Obama is also fueling discussions about new types of investments. This panel will explore the reasons for interest in investing in Personalized Medicine products and how both large and small companies are developing programs to expand their interest in this area.
Sue Siegel
CEO, GE Ventures & healthymagination, GE
- 2014 – 83 IPO Healthcare related
- 2015 – 64 IPO Healthcare related
- Regulatory and reimbursement
- Value based Pricing – hard to define, thus, hard to invest in some patient related innovations
- consumer driving value in the Financial Industry and Energy is creating Value why Healthcare is less taboo then Financial data
- 40% voted that a newborn will be sequenced at birth, what about in 10 years
- Hard time with Biomarkers and reimbursement
- PMI is an effort to COLLECT DATA paid by the Government so research will follow to edify the community on Public Health
Sean George, Ph.D. exCEO Navgenics
President, COO, and Co-Founder, Invitae
- what are the barriers related to Patient Value-based Pricing
- 10% of populations primary health issues are related to Genetics
- Uber example vs Genomics driver unknown in Uber, Results of genomic sequencing are not desired to become known
Mark Levin
Partner, Third Rock Ventures
- Drugs: Biologics
- Diagnostics and Prevention Medicine
- Big Data – MyoCardiac: data, Foundation Medicine: data
- Innovation that PMI will help to develop: The Molecular Statoscope: genome and other factors
- Chinese do not have Data on reimbursement and No legacy systems
- Investment in ALS, Parkinson, Regulation all diseases less on Cancers as investment focus
- CMS and Payer will benefit form PMI
Kimberly Popovits, ex-Genentech
Chairman of the Board, CEO and President, Genomic Health
- Precision Medicine progress depends on development of diagnostics
- Barriers by Technology, less and less so
- Payer do look at Diagnostics more favorable then in the Past
- Big Data more and more important
- cancer is a front runner in improvement of disease state
- Delivery of Value: Cancer Targeted Therapeutics workes only in 25% of the Cases – Shall we invest unless we achieve 60% working vs 25%
- Actionalbe Value from haveing the genome Sequence — >> change in Outcomes
- Roles fro CMS, Payers, FDA
– See more at: http://personalizedmedicine.partners.org/Education/Personalized-Medicine-Conference/Program.aspx#sthash.O4Znb9kq.dpuf
To Follow LIVE CONFERENCE COVERAGE PLEASE FOLLOW ON TWITTER USING
Meeting #: #PMConf
Meeting @: @HarvardPMConf
Overall good meeting #s:
#personalizedmedicine
#powerofgenomics
#genomics
#pharmanews
AND FOLLOW these @
@pharma_BI
@AVIVA_1950
@BiotechNews
TALK SPECIFIC # and @
8:30 AM | Special Guest Keynote Speaker Kathy Hudson, Ph.D. Deputy Director for Science, Outreach and Policy National Institutes of Health |
#NIH
#personalizedmedicine #pharma #healthcare #PublicHealth #HealthPolicy #clinicaltrial
|
@KathyHudsonNIH
|
9:00 AM | 9:00 a.m. – Panel Discussion Investments in Personalized Medicine
Sue Siegel Sean George, Ph.D. Kimberly Popovits
|
#personalizedmedicine
#venturecapital #startups #startup
#biotech #biopharma
|
@_SueSiegel
@VCapitalGuide @MassBio @MALifeSciences @FierceBiotech
|
Leave a Reply